857651-18-4

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(1-hydroxy-1-methylethyl)-, 1,1-dimethylethyl ester, (2S,4R)-
• CAS NO: 857651-18-4
• Molecular Formula: C18H37NO4Si
• Molecular Weight: 359.582
• Mol File: 857651-18-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(1-hydroxy-1-methylethyl)-, 1,1-dimethylethyl ester, (2S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(1-hydroxy-1-methylethyl)-, 1,1-dimethylethyl ester, (2S,4R)-(857651-18-4)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(1-hydroxy-1-methylethyl)-, 1,1-dimethylethyl ester, (2S,4R)-(857651-18-4)

Safety Data

• Hazardous Substances Data: 857651-18-4(Hazardous Substances Data)

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 1616435-07-4 4-(5-chloropyridin-3-yl)-N'-hydroxy-2-[(2S,4R)-4-methoxy-2-(propan-2-yl)pyrrolidin-1-yl]-3-[(trans-4-methylcyclohexyl)methyl]-3H-imidazo[4,5-c]pyridine-6-carboximidamide 
• 1616435-06-3 4-(5-chloropyridin-3-yl)-2-[(2S,4R)-4-methoxy-2-(propan-2-yl)pyrrolidin-1-yl]-3-[(trans-4-methylcyclohexyl)methyl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile 
• 1616435-05-2 4-(5-chloropyridin-3-yl)-2-[(2S,4R)-4-hydroxy-2-(propan-2-yl)pyrrolidin-1-yl]-3-[(trans-4-methylcyclohexyl)methyl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile 
• 1616429-62-9 3-{4-(5-chloropyridin-3-yl)-2-[(2S,4R)-4-methoxy-2-(1-methylethyl)pyrrolidin-1-yl]-3-[(trans-4-methylcyclohexyl)methyl]-3H-imidazo[4,5-c]pyridin-6-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1212437-79-0 tert-butyl (2S)-4-oxo-2-(propan-2-yl)pyrrolidine-1-carboxylate 
• 149396-15-6 (2S,4R)-N-t-butoxycarbonyl-4-t-butyldimethylsilyloxy-2-[N-(p-toluenesulfonyl)azetidin-3-yl]pyrrolidine 

Relevant articles and documents

Substituted Imidazopyridines as HDM2 Inhibitors

The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.